• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Am Acad Dermatol . Risk of Autoimmune Skin and Connective Tissue Disorders After mRNA-based COVID-19 Vaccination

tetano

Editor, Senior Moderator
J Am Acad Dermatol


. 2023 May 13;S0190-9622(23)00829-0.
doi: 10.1016/j.jaad.2023.05.017. Online ahead of print. Risk of Autoimmune Skin and Connective Tissue Disorders After mRNA-based COVID-19 Vaccination

Hyun Jeong Ju[SUP] 1 [/SUP], Ju Yeong Lee[SUP] 2 [/SUP], Ju Hee Han[SUP] 3 [/SUP], Ji Hae Lee[SUP] 1 [/SUP], Jung Min Bae[SUP] 1 [/SUP], Solam Lee[SUP] 4 [/SUP]



Affiliations
Abstract

Background: Data on the association between the development of autoimmune diseases and coronavirus disease 2019 (COVID-19) vaccination are limited.
Objective: To investigate the incidence and risk of autoimmune connective tissue disorders following mRNA-based COVID-19 vaccination.
Methods: This nationwide population-based study was conducted in South Korea. Individuals who received vaccination between September 8, 2020-December 31, 2021, were identified. Historical pre-pandemic controls were matched for age and sex in 1:1 ratio. The incidence rate and risk of disease outcomes were compared.
Results: A total of 3,838,120 vaccinated individuals and 3,834,804 controls without evidence of COVID-19 were included. The risk of alopecia areata, alopecia totalis, primary cicatricial alopecia, psoriasis, vitiligo, anti-neutrophil cytoplasmic antibody-associated vasculitis, sarcoidosis, Behcet disease, Crohn disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjogren syndrome, ankylosing spondylitis, dermato/polymyositis, and bullous pemphigoid was not significantly higher in vaccinated individuals than in controls. The risk was comparable according to age, sex, type of mRNA-based vaccine, and cross-vaccination status.
Limitations: Possible selection bias and residual confounders.
Conclusion: These findings suggest that most autoimmune connective tissue disorders are not associated with a significant increase in risk. However, caution is necessary when interpreting results for rare outcomes due to limited statistical power.

Keywords: COVID-19; autoimmune disease; connective tissue disease; epidemiology; mRNA; risk; skin disease; vaccination.

 
Back
Top Bottom